Medibrane
Contract Manufacturing of polymer solvent based processes
Company Overview
Snapshot
Founded in May 2015 by Elad Einav and Amir Kraitzer, Medibrane operates with 11–50 employees. The company has received funding across two rounds from two investors. In June 2019, Medibrane secured investment and debt financing from Resonetics.
Business overview
Medibrane specializes in contract manufacturing, focusing on solvent-based polymeric deposition processes for medical invasive devices. The company's core technology involves materials and polymers, serving the medical devices industry within the broader healthcare and life sciences market. Medibrane's offerings include contract services for medical products, primarily targeting markets in Europe, North America, and India.
Strategic signal
In March 2023, Medibrane's expertise in applying polymeric covers to stents and laser-cut hypotubes was highlighted in a podcast featuring CEO Elad Einav. This signals the company's continued leadership and technical validation in specialized medical device manufacturing, reinforcing its position as a key partner for advanced invasive device development.
Log in to access full profile ›Company Intelligence Q&A
- When was Medibrane founded and by whom?
- Medibrane was founded in May 2015 by Co-founder & CEO Elad Einav and Co-founder & CTO Amir Kraitzer.
- What is Medibrane's primary business activity?
- Medibrane is a contract manufacturer specializing in solvent-based polymeric deposition processes for medical invasive devices.
- Which investor participated in Medibrane's June 2019 funding round?
- In June 2019, Medibrane received investment and debt financing from Resonetics, as reported by FinSMEs on June 16, 2019, and Globes on June 23, 2019.
- What strategic alliance did Medibrane form in January 2017?
- In January 2017, Medibrane formed a strategic alliance with AdvanSource Biomaterials.
- What was a key topic discussed by Medibrane's CEO in October 2019?
- In October 2019, Medibrane's CEO discussed new technologies to treat and prevent strokes, highlighting the company's engagement with critical medical advancements.